Verastem initiates VS-5584 clinical trial Verastem announced the initiation of a Phase 1 trial of VS-5584 in patients with advanced solid tumors or lymphoma. Verastem presented preclinical research in 2013 on the ability of VS-5584 to preferentially target cancer stem cells. Study data demonstrated that VS-5584 has equipotency against all four human Class I PI3K isoforms and both the mTORC1 and mTORC2 complexes of the mTOR kinase. VS-5584 decreased cancer stem cells across multiple in vitro and in vivo cancer models including triple negative breast cancer, small cell lung cancer and ovarian cancer. This is in contrast to the effect of standard of care treatments like chemotherapy which increase the proportion of cancer stem cells in these studies. The Phase 1 open-label, dose escalation and schedule finding study is designed to assess the safety, pharmacokinetics, pharmacodynamics and initial clinical activity of single agent VS-5584. The study will enroll up to 62 patients. The company said, "We look forward to 2014 when we expect additional clinical data from these trials will become available.”
News For VSTM From The Last 14 Days
Check below for free stories on VSTM the last two weeks.